Pregnane receptor gene polymorphisms, pathogenic bacteria distribution and drug sensitivity, and TCM syndrome differentiation in patients with cholelithiasis.
暂无分享,去创建一个
Lei Peng | B. Fang | Shuang Zhou | Yiqiang Xie | Jingzhe Zhang | Hua Zhang | Chuan-Zhu Lyu | Li-Zhuo Li
[1] M. Huang,et al. Hepatoprotective Effects of Schisandra sphenanthera Extract against Lithocholic Acid–Induced Cholestasis in Male Mice Are Associated with Activation of the Pregnane X Receptor Pathway and Promotion of Liver Regeneration , 2016, Drug Metabolism and Disposition.
[2] Xi Ma,et al. Pregnane X Receptor as the “Sensor and Effector” in Regulating Epigenome , 2015, Journal of cellular physiology.
[3] M. Trauner,et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. , 2015, Journal of hepatology.
[4] Byung-Hoon Lee,et al. Expression of CYP3A in chronic ethanol-fed mice is mediated by endogenous pregnane X receptor ligands formed by enhanced cholesterol metabolism , 2015, Archives of Toxicology.
[5] Se-hyung Park,et al. Intestinal pregnane X receptor links xenobiotic exposure and hypercholesterolemia. , 2015, Molecular Endocrinology.
[6] F. Baldelli,et al. Targeting FXR in cholestasis: hype or hope , 2014, Expert opinion on therapeutic targets.
[7] Hui Tang,et al. Cholelithiasis and risk of pancreatic cancer: systematic review and meta-analysis of 21 observational studies , 2014, Cancer Causes & Control.
[8] J. Cullen,et al. Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice. , 2014, Biochemical pharmacology.
[9] Minarda De la O-Arciniega,et al. Intestinal and hepatic Niemann-Pick C1L1 proteins: future therapeutic targets for cholesterol gallstones disease? , 2014, European journal of pharmacology.
[10] M. Büchler,et al. Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation , 2013, Endoscopy.
[11] B. Liu,et al. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study , 2013, BMC Genomics.
[12] I. Kotta-Loizou,et al. Pregnane X receptor polymorphisms associated with human diseases , 2013, Expert opinion on therapeutic targets.
[13] P. Portincasa,et al. Current Views on Genetics and Epigenetics of Cholesterol Gallstone Disease , 2013, Cholesterol.
[14] S. Zeng,et al. Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond , 2013, Expert opinion on drug metabolism & toxicology.
[15] W. Xie,et al. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. , 2012, Trends in pharmacological sciences.
[16] M. Downes,et al. FXR and PXR: Potential therapeutic targets in cholestasis , 2012, The Journal of Steroid Biochemistry and Molecular Biology.
[17] M. Makishima,et al. PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts. , 2011, Gastroenterology.